Forest Laboratories Revises Fiscal 2013 Earnings Guidance Primarily Due to Evolving Conditions in the Lexapro Market

Forest Laboratories announced revised FY 2013 earnings guidance. Following the expiration of Lexapro’s patent exclusivity in March, rapidly evolving and unanticipated conditions in the Lexapro (escitalopram) market necessitate revisions to the company’s previous forecasts for both branded Lexapro sales and royalty income earned on sales of the escitalopram authorized generic, distributed by an independent third party.
Yahoo! Finance